JY
RLMD icon

Jeff Yass’s Relmada Therapeutics RLMD Stock Holding History

Jeff Yass’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$527K Sell
76,100
-205,700
-73% -$1.44M ﹤0.01% 9805
2026
Q1 		$1.96M Buy
281,800
+234,600
+497% +$1.11M ﹤0.01% 6226
2025
Q4 		$228K Sell
47,200
-18,800
-28% -$63K ﹤0.01% 10580
2025
Q3 		$133K Buy
+66,000
New +$63.3K ﹤0.01% 11379
2025
Q1 		– Sell
-209,900
Closed -$109K – 13300
2024
Q4 		$109K Buy
209,900
+82,600
+65% +$201K ﹤0.01% 11270
2024
Q3 		$412K Buy
127,300
+97,000
+320% +$314K ﹤0.01% 8932
2024
Q2 		$90.9K Buy
30,300
+6,500
+27% +$23.5K ﹤0.01% 11088
2024
Q1 		$111K Buy
+23,800
New +$115K ﹤0.01% 11152
2023
Q1 		– Sell
-145,400
Closed -$507K – 13347
2022
Q4 		$507K Sell
145,400
-71,500
-33% -$628K ﹤0.01% 7827
2022
Q3 		$8.03M Buy
216,900
+73,900
+52% +$2.05M ﹤0.01% 2465
2022
Q2 		$2.72M Buy
143,000
+23,300
+19% +$508K ﹤0.01% 4256
2022
Q1 		$3.23M Buy
119,700
+49,400
+70% +$1.02M ﹤0.01% 4485
2021
Q4 		$1.58M Buy
70,300
+9,700
+16% +$216K ﹤0.01% 6081
2021
Q3 		$1.59M Buy
60,600
+3,500
+6% +$93.7K ﹤0.01% 6341
2021
Q2 		$1.83M Sell
57,100
-22,800
-29% -$792K ﹤0.01% 6122
2021
Q1 		$2.81M Buy
79,900
+36,400
+84% +$1.27M ﹤0.01% 5109
2020
Q4 		$1.4M Sell
43,500
-22,100
-34% -$759K ﹤0.01% 5907
2020
Q3 		$2.47M Sell
65,600
-6,800
-9% -$263K ﹤0.01% 4223
2020
Q2 		$3.24M Buy
72,400
+47,400
+190% +$2M ﹤0.01% 3670
2020
Q1 		$853K Sell
25,000
-2,800
-10% -$113K ﹤0.01% 5754
2019
Q4 		$1.08M Buy
+27,800
New +$845K ﹤0.01% 5375

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jeff Yass's RLMD Position: Q2 2026 in Review

Jeff Yass reduced its Relmada Therapeutics (RLMD) stake by 97% in Q2 2026, selling an estimated $6.86M and leaving 30,108 shares worth $208K. The position accounts for ﹤0.01% of the portfolio, ranked #11861.

Jeff Yass first reported a position in RLMD in Q4 2019 and has held it in 21 quarters since. The position peaked at $7.04M in Q1 2026. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Jeff Yass held 30,108 shares of Relmada Therapeutics worth $208K as of Q2 2026.
  • Jeff Yass sold 981,464 Relmada Therapeutics shares in Q2 2026, an estimated $6.86M.
  • Relmada Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #11861 holding.
  • Jeff Yass first reported a position in Relmada Therapeutics in Q4 2019 and has held it in 21 quarters since.
  • Jeff Yass's Relmada Therapeutics position peaked at $7.04M in Q1 2026.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.